# Junta clínica — PT-pseudo_c39e94a13920 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_c39e94a13920",
  "pid": "PT-pseudo_c39e94a13920",
  "task": 1,
  "psa": 12.4,
  "age": 67,
  "months": 3,
  "pirads": "3",
  "psad": 0.08,
  "psav": 1.58,
  "psap": 11.3,
  "vol": 149.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.58010316,
  "medhx": "Hypercholesterolaemia, Chronic kidney disease, Osteoarthritis, Benign prostatic hyperplasia",
  "meds": "atorvastatin, rosuvastatin",
  "notes": "PSA 12.4 ng/mL. PI-RADS 3. PSAD 0.08. Prostate volume 149 mL. csPCa 0.58.",
  "pmhx": [
    "Hypercholesterolaemia",
    "Chronic kidney disease",
    "Osteoarthritis",
    "Benign prostatic hyperplasia"
  ],
  "allergies": [],
  "vitals": {
    "weight": "91 kg",
    "height": "178 cm",
    "bmi": "28.7",
    "bp": "128/89 mmHg",
    "hr": "70 bpm",
    "smoking": "Ex-smoker (19 pack-yr, quit 2016)",
    "last_dental": "2 yr ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "03 Jan 2025",
  "enc_ref": "Dr. M. Jansen (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Clinical review sought due to sustained PSA elevation and a previously positive biopsy result."
    },
    {
      "s": "History",
      "t": "A 67-year-old married graphic designer residing with his partner, who receives weekly visits from his adult children, presents for this assessment. Initial symptoms included mild lower urinary tract complaints (IPSS 7/35), prompting surveillance that began in mid-2023. His medical background encompasses hypercholesterolaemia treated with atorvastatin and rosuvastatin, stage 3 chronic kidney disease (creatinine 166 umol/L, eGFR <60), and knee osteoarthritis. He ceased smoking in 2016 after accumulating 19 pack-years and sustains a fitness regimen of 5 km runs three times weekly, alongside a modest alcohol intake of four units per week. Recent interventions include a six-session physiotherapy course for mechanical lower back pain and routine endocrinology thyroid screening, both remaining clinically stable. While he reports occasional fatigue, he attributes this to visual impairment requiring large-print materials and expresses no particular anxiety regarding his prostate cancer history."
    },
    {
      "s": "Physical examination",
      "t": "DRE — prostate: symmetrically enlarged, smooth, firm; no palpable nodules or asymmetry detected. General inspection reveals no abnormalities. Cardiovascular and respiratory auscultation are normal. Peripheral oedema and lymphadenopathy are absent."
    }
  ],
  "occupation": "graphic designer",
  "marital": "Married",
  "living": "Lives with partner; adult children visit weekly",
  "next_of_kin": "Long-time friend (no close family)",
  "recent_other": [
    "Physiotherapy — lower back, six sessions",
    "Endocrine — thyroid screening"
  ],
  "alcohol": "4 units / week",
  "exercise": "Running 3x/week, 5 km",
  "ipss": "IPSS score: 7/35 (mild LUTS)",
  "admin": "Visual impairment: large-print correspondence requested.",
  "mri_hospital": "Amsterdam UMC (location VUmc)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_c39e94a13920
Task: 1

Encounter: Urology - outpatient on 03 Jan 2025.
Referrer: Dr. M. Jansen (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 12.4 ng/mL
  - mpMRI — PI-RADS score: 3 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.08 ng/mL²
  - PSA velocity: 1.58 ng/mL/yr
  - Prior PSA: 11.3 ng/mL
  - Prostate volume: 149.0 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.58010316 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypercholesterolaemia, Chronic kidney disease, Osteoarthritis, Benign prostatic hyperplasia
  - Problem list / PMHx: Hypercholesterolaemia, Chronic kidney disease, Osteoarthritis, Benign prostatic hyperplasia
  - Current medication: atorvastatin, rosuvastatin
  - Allergies: NKA
  - Additional notes: PSA 12.4 ng/mL. PI-RADS 3. PSAD 0.08. Prostate volume 149 mL. csPCa 0.58.

Vitals: weight 91 kg, height 178 cm, BMI 28.7, BP 128/89 mmHg, HR 70 bpm. Smoking: Ex-smoker (19 pack-yr, quit 2016).

Chief complaint: Clinical review sought due to sustained PSA elevation and a previously positive biopsy result.

History: A 67-year-old married graphic designer residing with his partner, who receives weekly visits from his adult children, presents for this assessment. Initial symptoms included mild lower urinary tract complaints (IPSS 7/35), prompting surveillance that began in mid-2023. His medical background encompasses hypercholesterolaemia treated with atorvastatin and rosuvastatin, stage 3 chronic kidney disease (creatinine 166 umol/L, eGFR <60), and knee osteoarthritis. He ceased smoking in 2016 after accumulating 19 pack-years and sustains a fitness regimen of 5 km runs three times weekly, alongside a modest alcohol intake of four units per week. Recent interventions include a six-session physiotherapy course for mechanical lower back pain and routine endocrinology thyroid screening, both remaining clinically stable. While he reports occasional fatigue, he attributes this to visual impairment requiring large-print materials and expresses no particular anxiety regarding his prostate cancer history.

Physical examination: DRE — prostate: symmetrically enlarged, smooth, firm; no palpable nodules or asymmetry detected. General inspection reveals no abnormalities. Cardiovascular and respiratory auscultation are normal. Peripheral oedema and lymphadenopathy are absent.

Patient info: graphic designer; Married; Lives with partner; adult children visit weekly.
Next of kin: Long-time friend (no close family).

Lifestyle: alcohol 4 units / week; exercise Running 3x/week, 5 km; IPSS score: 7/35 (mild LUTS).

Recent other appointments: Physiotherapy — lower back, six sessions; Endocrine — thyroid screening.
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-CLASSIFIER

*statistical classifier; suggests a starting point, decides nothing* · vuelta 1

A classifier trained only to open the discussion, not to close it. Here is its bid.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.47
  uncertainty  +/- 0.18 (95% CI 0.11-0.83); among patients it cannot tell apart the outcome was 1.00 of 1.00 mixed
  confidence   LOW — in this tier it was right 49% of the time over 43 labelled cases — barely better than a coin, so treat it as an opening bid and nothing more

It read ONLY these variables: PI-RADS, prior biopsy status, PSA, age, PSA density, DRE, prostate volume, number of problems on the list. Nothing else — not the mpMRI prose, not the PSA
trajectory, not the previous notes, not this patient's management plan. Values it could not
read for this patient: none.
Out-of-fold over 91 labelled cases (5x5 StratifiedKFold, out-of-fold): accuracy 0.714 against a
majority-class baseline of 0.615, AUC 0.789, F1(yes) 0.78.

The final call is the senior urologist's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. I have no answer for him, and that is the finding.

The criterion here is that the visible panel does not determine this decision: the man already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. Measured on the 49 labelled cases in this
situation: no structured variable separates the two answers — PSA is rising in all 49 — the
split is 26 defer / 23 biopsy, and every rule fitted on one half failed on the other.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle
this man and the retrieved documents have to.

## Intervención 5 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline discusses using a PI-RADS threshold of $\ge 3$ to trigger a biopsy, noting that this may avoid missing some ISUP Grade Group 2 cancers in biopsy-naïve patients. It also mentions that a stable MRI (PRECISE 1-3) does not make repeat biopsy superfluous but might be excluded in patients with low-risk tumour and a stable PSA-D $< 0.15$.

WHAT THE CLASSIFIER'S BID DOES NOT SETTLE
The classifier's suggestion of "NO BIOPSY" is not sufficiently informed by the guideline because it fails to account for the specific interplay between the PI-RADS score and the PSA density threshold mentioned in the guideline. The guideline suggests that a PI-RADS $\ge 3$ threshold is used, and the classifier's bid does not incorporate the risk-adapted matrix that links PI-RADS scores with PSA density to guide the decision.

WHAT WE STILL NEED
The mpMRI prose - the mpMRI prose shows a PI-RADS score of 3. The guideline suggests using a PI-RADS $\ge 3$ threshold to trigger biopsy. The patient's prior biopsy status is "Positive," which is a critical factor the guideline makes decisive. The PSA density is $0.08 \text{ ng/mL}^2$, which is below the $0.15 \text{ ng/mL}^2$ threshold mentioned in the guideline.

## Intervención 6 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 1

This case hinges on how the PI-RADS 3 score interacts with the prior positive biopsy result, especially given the low PSA density.

Before anyone argues, this is what I want established, and by whom.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Determine the mpMRI prose, including lesion size, zone, and extraprostatic extension.
  psa_trend (get_psa_trend) -> Determine the PSA trend to assess the PSA velocity.
  previous_notes (get_previous_notes) -> Review the previous notes to understand the management context and prior biopsy findings.

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. What is the full mpMRI prose to assess the lesion characteristics?
  Q2. Does the mpMRI prose provide information on extraprostatic extension?

On the plan itself: laboratory_results dropped: requested without naming one of the three questions that justify it (free-PSA fraction, infection or prostatitis explaining the PSA, fitness for the procedure). The DRE and the headline PSA are already on the panel.

## Intervención 7 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The mpMRI prose shows a PI-RADS 3 lesion located in the right peripheral zone at the mid-gland level, spanning roughly 14 x 11 x 10 mm. It does not provide information on extraprostatic extension.
psa_trend
The PSA trend shows values: Aug 2023: 2.2 ng/mL, Dec 2023: 3.4 ng/mL, Apr 2024: 5.2 ng/mL, Aug 2024: 8.0 ng/mL, Jan 2025: 12.4 ng/mL.
previous_notes
The previous notes indicate that on 13 Jul 2023, a PSA level of 7.1 ng/mL prompted a urological referral for multiparametric MRI and further risk stratification.

WHAT I DID NOT OPEN
I did not open the laboratory_results because the moderator did not explicitly ask for it in the plan, and the DRE and headline PSA were already on the panel.

WHAT THIS SUPPORTS
FOR sampling this patient now
The mpMRI prose identifies a PI-RADS 3 lesion, which aligns with the EAU guideline suggesting a PI-RADS $\ge 3$ threshold for biopsy.
The PSA trend shows a clear upward trajectory, with the PSA increasing from 2.2 ng/mL in Aug 2023 to 12.4 ng/mL in Jan 2025.
AGAINST sampling this patient now
The prior biopsy result is documented as "Positive," which is a critical factor the guideline makes decisive.
The cohort criterion indicates that the panel cannot settle the decision, as the split between defer and biopsy was 26 defer / 23 biopsy in the 49 labelled cases.

WHERE THIS LEANS
The data suggests a need for further characterization given the PI-RADS 3 score and the prior positive biopsy, leaning towards biopsy.
LEAN: biopsy

## Intervención 8 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The registrar answered Q1 by providing the mpMRI prose, which details a PI-RADS 3 lesion in the right peripheral zone, and answered Q2 by stating it did not provide information on extraprostatic extension.

ALIGNMENT WITH THE CLASSIFIER
The retrieved evidence leans towards biopsy, which disagrees with the EXPERT-CLASSIFIER's suggestion of "NO BIOPSY" (p=0.47), as the evidence highlights the PI-RADS 3 score and the rising PSA trend.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the full mpMRI prose to assess the lesion characteristics? Answered by the REGISTRAR with the mpMRI prose showing a PI-RADS 3 lesion.
Q2. Does the mpMRI prose provide information on extraprostatic extension? Answered by the REGISTRAR that it does not provide this information.

WHAT CARRIES WEIGHT, AND WHY
The relevant variables are the PI-RADS score (3), which matters because the EAU guideline suggests a $\ge 3$ threshold for biopsy, and the PSA trend, which matters because it shows a clear upward trajectory, indicating progression. The prior positive biopsy result is a variable the cohort criterion suggests does not settle the decision, but the combination of PI-RADS 3 and rising PSA supports further investigation. The guideline does not explicitly support deferral when PI-RADS $\ge 3$ is present.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with a biopsy to further characterize the PI-RADS 3 lesion, given the guideline threshold and the rising PSA trend, despite the prior positive biopsy.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 9 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

Despite the prior positive biopsy, the PI-RADS 3 score and the clear upward PSA trend strongly support further characterization. The EAU guideline suggests a PI-RADS $\ge 3$ threshold for biopsy, and the rising PSA indicates progression. The combination of these factors, supported by the retrieved MRI prose, justifies proceeding with a biopsy to determine the current disease status.

What carried weight: bx=important, age=important, psa=important, vol=noted, psad=important, cspca=noted, pirads=decisive, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes
